Myocardial protection by glucose�밿nsulin�뱎otassium in acute coronary syndrome patients undergoing urgent multivessel off-pump coronary artery bypass surgery by 怨쎌쁺�� et al.
Myocardial protection by glucose–insulin–potassium
in acute coronary syndrome patients undergoing urgent
multivessel off-pump coronary artery bypass surgery
J.-K. Shim1, S.-Y. Yang3, Y.-C. Yoo1, K.-J. Yoo2 and Y.-L. Kwak1,4*
1 Department of Anaesthesiology and Pain Medicine, Anaesthesia and Pain Research Institute and 2 Department of Cardiothoracic Surgery,
Yonsei University Health System, 250 Seongsanno, Seodaemun-Gu, Seoul 120-752, Republic of Korea
3 Department of Anaesthesiology and Pain Medicine, Chung-Ang University College of Medicine, Seoul, Republic of Korea
4 Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
* Corresponding author. E-mail: ylkwak@yuhs.ac
Editor’s key points
† Effects of glucose–
insulin–potassium (GIK)
infusion on myocardial
damage during coronary
artery surgery were
studied.
† Biomarkers of myocardial
damage were measured
after reperfusion of the
heart in patients with or
without the ongoing
infusion.
† GIK attenuated the levels
of creatinine kinase-MB
and troponin-T.
† This study provides
biochemical evidence of
myocardial protective
role of GIK infusion.
Background. The aim of this randomized and controlled trial was to investigate the effect of
a glucose–insulin–potassium (GIK) solution on myocardial protection in acute coronary
syndrome (ACS) patients undergoing urgent multivessel off-pump coronary artery bypass
(OPCAB) surgery.
Methods. Sixty-six patients were randomly allocated either to receive 0.3 ml kg21 h22 GIK
solution (potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose) or
equivalent volume of normal saline (control) upon anaesthetic induction until 6 h after
reperfusion. The primary endpoints were to compare the concentrations of creatine
kinase-MB (CK-MB) and troponin-T between the groups after reperfusion. The secondary
endpoints were to compare the incidences of postoperative troponin-T .0.8 ng ml21 and
myocardial infarction (MI) between the groups.
Results. Highest CK-MB [8.7 (4.4) vs 13.1 (7.9) ng ml21, P¼0.006] and troponin-T [0.20
(0.13–0.49) vs 0.48 (0.18–0.91) ng ml21, P,0.0001] values after reperfusion were
significantly lower in the GIK group compared with the control group. The area under the
curve of serially measured troponin-T was also significantly smaller in the GIK group
compared with the control group [0.83 (0.43–1.81) vs 0.46 (0.31–1.00), P¼0.036].
Significantly fewer patients in the GIK group showed troponin-T .0.8 ng ml21 after
reperfusion compared with the control group (3 vs 11, P¼0.033). The incidence of
postoperative MI was similar between the groups.
Conclusions. GIK administration in ACS patients undergoing urgent multivessel OPCAB
significantly attenuated the degree of ensuing myocardial injury without complications
related to glycaemic control.
Clinical Trial Registry. URL: http://clinicaltrials.gov/ct2/show/NCT01384656?term=GIK+
AND+OPCAB&rank=1. Unique identification number NCT01384656.
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In patients with multivessel coronary artery disease and
acute coronary syndrome (ACS), urgent coronary artery
bypass surgery (CABG) is a well-established treatment. Unfor-
tunately, these patients are at increased risk of myocardial
infarction (MI), rehospitalization, and cardiac death after
CABG compared with patients with stable angina pectoris.1 2
Recently, off-pump CABG (OPCAB) is gaining renewed
interest for being associated with improved outcome in high-
risk patients compared with on-pump CABG.3 4 In patients
with ACS presenting for emergent CABG, OPCAB was also
associated with improved hospital outcome.5 Moreover, in
the era of dual antiplatelet therapy, OPCAB may especially
be valuable for ACS patients, as it has been safely performed
without increased risk of procedural bleeding in patients on
continued clopidogrel therapy close to surgery.6 7
Although different from the global myocardial ischaemia–
reperfusion injury observed in on-pump CABG, multivessel
OPCAB produces cumulative warm regional myocardial
ischaemia–reperfusion injury.8 Accordingly, the myocardium
remains vulnerable to various degrees of injury with
unavoidable periods of regional myocardial stunning and
impaired cardiac performance.9 Thus, an effective myocardial
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protective strategy, especially in high-risk patients such as ACS
patients requiring urgent surgical revascularization, seems to
be mandatory.
In order to minimize ischaemic myocardial injury,
glucose–insulin–potassium (GIK) solution has been used
for almost five decades in various clinical settings for its
metabolic and non-metabolic cardioprotective mechanisms.
GIK as an adjunct to revascularization after acute MI
has been shown to offer significant survival benefit.10 In
the cardiac surgical setting, a recent meta-analysis
also showed beneficial effects of GIK solution in terms of
reduced myocardial injury and improved haemodynamic
performance.11 Yet, evidence regarding the myocardial pro-
tective effect of GIK in ACS patients undergoing OPCAB is
lacking.
The aim of this prospective, single-site, double-blind, ran-
domized, and parallel-arm controlled trial was to investigate
the effect of a GIK solution on myocardial protection in ACS
patients undergoing urgent OPCAB. The primary endpoints
were to compare the concentrations of creatine kinase-MB
(CK-MB) and troponin-T between the groups during the
perioperative period as markers of myocardial injury. The
secondary endpoints were to compare the incidences of
troponin-T .0.8 ng ml21,12 postoperative MI, and outcome
between the groups.
Methods
Patients
After Institutional Review Board approval and written
informed consent was obtained, 66 patients with ACS requir-
ing urgent multivessel OPCAB between February 2011 and
October 2011 at Severance Hospital were prospectively
studied. This study was registered with ClinicalTrials.gov
(Ref: NCT01384656). Urgency was defined as OPCAB
performed during the index admission within 2 days of
diagnosis-confirmation by coronary angiography. Patients
were randomly allocated to either the GIK or the control
group in 1:1 ratio by means of random numbers generated
by a computer. An anaesthesiologist not involved in the
current trial performed randomization and assignment.
Exclusion criteria were emergent and/or redo surgery,
insulin-dependent diabetes, serum fasting blood glucose
concentration .13.8 mmol litre21, liver dysfunction, con-
firmed renal impairment [serum creatinine (Cr) .2 mg
dl21], mechanical cardiopulmonary support (patients who
are already on mechanical ventilation, intra-aortic balloon
pump, or both before operation), and emergency conversion
to an on-pump CABG. We had not excluded patients with
recent MI as we enrolled ACS patients, which encompass
patients with non-ST elevation MI, ST elevation MI, and
unstable angina (data provided in Table 1). There was no
lower limit for the left ventricular ejection fraction (LVEF).
However, we excluded patients who were already on
intra-aortic balloon pump before operation due to severe
heart failure and haemodynamic compromise as described
above.
Treatment
Patients in the GIK group received 0.3 ml kg21 h22 GIK solu-
tion (potassium 80 mEq and regular insulin 325 IU in 500 ml
of 50% glucose) via the central venous route upon anaes-
thetic induction until 6 h after reperfusion. Patients in the
control group received equivalent volume of normal saline
for the same duration. Solutions were prepared by an anaes-
thesia nurse and administered by an anaesthesiologist who
were both not involved in this study. Attending surgeon
and anaesthesiologist involved in the patient care were
blinded to the patients’ groups.
In all patients, arterial blood gas analyses were performed
every hour until discontinuation of the treatment or placebo.
Serum glucose concentration was serially measured by arter-
ial blood gas analysis and was maintained between 4 and 11
mmol litre21 using regular insulin or 50% glucose, as neces-
sary. Serum potassium concentration was also serially mea-
sured by arterial blood gas analysis and maintained between
3.5 and 5.5 mEq litre21.
Perioperative management
All patients received standardized perioperative care.
Standard monitoring included a pulmonary artery catheter
(Swan–Ganz CCOmbo CCO/SvO2TM, Edwards Lifesciences
Table 1 Patients’ characteristics. Values are mean (range) for age,
mean (SD) or number of patients (%). GIK, glucose–insulin–
potassium; MI, myocardial infarction
Control
(n533)
GIK (n533) P-value
Age (yr) 67 (7–79) 64 (48–76) 0.157
Gender (M/F) 23/10 20/13 0.606
Body mass index (kg m22) 24 (3) 24 (3) 0.949
Left ventricular ejection
fraction (%)
39 (9) 35 (11) 0.089
Diabetes 12 (36) 19 (58) 0.138
Hypertension 17 (52) 19 (58) 0.805
Recent MI (,1 month) 13 (39) 16 (49) 0.620
Unstable angina/non
ST-elevation MI
31 (94) 30 (91) 1.000
ST-elevation MI 2 (6) 3 (9) 1.000
Left main disease 3 (9) 5 (15) 0.708
Degree of stenosis (%)
Left anterior descending 82 (13) 86 (10) 0.195
Left circumflex 80 (21) 77 (26) 0.684
Right coronary artery 83 (14) 85 (15) 0.773
Creatinine (mg dl21) 1.0 (0.2) 1.0 (0.2) 0.321
Medications
Nitrates 5 (15) 7 (21) 0.751
b-Blockers 22 (67) 22 (67) 1.000
Calcium channel blockers 12 (36) 8 (24) 0.422
Renin–angiotensin
system antagonists
17 (52) 20 (61) 0.620
Statins 11 (35) 9 (28) 0.595
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LLC, Irvine, CA, USA) and transoesophageal echocardiog-
raphy. Anaesthesia was induced with midazolam (0.05–
0.07 mg kg21) and sufentanil (1.5–2 mg kg21), and then
maintained with sufentanil (1.0–1.5 mg kg21 h22) with sevo-
flurane (0.8–1.5%) to maintain the bispectral index score
between 40 and 60. Neuromuscular block was achieved
with rocuronium.
All surgical procedures were performed by a single surgical
team through a full sternotomy incision. During grafting, the
heart was displaced using a posterior pericardial stitch, large
gauze (12×70 cm) swabs, and a suction-type tissue stabil-
izer. Routine sequence of revascularization was as follows.
The left internal thoracic artery was grafted to the left anter-
ior descending coronary artery first, followed by revasculari-
zations of the diagonal branch, left circumflex coronary
artery, and the right coronary artery as required. These
were achieved by way of composite graft reconstruction
using the radial artery or the saphenous vein to the left
or the right internal thoracic artery, and/or by using the
saphenous vein anastomized to the ascending aorta, or
both, as necessary.
Major goals of haemodynamic management were to
maintain mixed venous oxygen saturation (SvO2 ) . 60%
and the mean systemic arterial pressure between 60 and
80 mm Hg. Milrinone (0.3–0.5 mg kg21 min22) was infused
in patients with SvO2 , 60% for .10 min, despite the opti-
mization of preload and haematocrit and/or newly developed
mitral regurgitation ≥grade 3 with a concomitant increase in
the mean pulmonary arterial pressure .30 mm Hg during
grafting. During grafting, emergency conversion to an
on-pump CABG was considered when SvO2 , 50% or newly
developed mitral regurgitation ≥grade 3 persisted, despite
aggressive treatment or when intractable dysrhythmia had
developed. All patients were transferred to the intensive
care unit (ICU) after the operation. In the ICU, milrinone
was infused when cardiac index was ,2.0 litre min21 m22
or SvO2 was ,60%, despite the optimization of other deter-
minants of cardiac output. An intra-aortic balloon pump
was inserted when cardiac index ,2.0 litre min21 m22 or
SvO2 , 60% persisted with worsening lactic acidosis,
despite aggressive treatment. Packed erythrocytes were
transfused when haematocrit was ,25% throughout the
study period.
Endpoints
The primary endpoints were to compare the highest concen-
trations of CK-MB and troponin-T between the groups after
reperfusion as markers of myocardial injury. Also, the area
under the curve (AUC) of serially measured troponin-T was
compared between the groups. CK-MB (normal range ,5
ng ml21) and troponin-T (normal range ,0.1 ng ml21)
were measured immediately before operation, and at 12,
24, and 48 h after reperfusion.
The secondary endpoints were to compare the incidences
of postoperative troponin-T .0.8 ng ml21,12 MI, and compos-
ite morbidity endpoint between the groups. MI was defined
as the occurrence of increase in troponin-T .0.5 ng ml21
(five times above the upper normal limit) and the develop-
ment of new pathological Q-waves or new left bundle
branch block.13 Composite morbidity endpoint was defined
as the presence of any of the following major morbidity end-
points including MI and in-hospital mortality: (i) permanent
stroke, (ii) renal dysfunction, (iii) haemostatic reoperation,
(iv) deep sternal wound infection, and (v) prolonged ventila-
tion .48 h.14
Clinical evaluations
Assessed preoperative variables included patient characteris-
tic data, co-morbid conditions, LVEF, history of recent MI (,1
month), presence of left main disease, degree of stenosis of
the diseased coronary arteries, and medications.
Assessed intraoperative variables included the duration
of the operation, number of grafts performed, total graft
reconstruction time, fluid balance, and use of milrinone.
Also, haemodynamic variables including SvO2 , cardiac index,
heart rate, mean systemic arterial pressure, central venous
pressure, mean pulmonary arterial pressure, and pulmonary
artery occlusion pressure were recorded at 10 min after an-
aesthetic induction (T1), 10 min after stabilizer application
for grafting at the obtuse marginalis branch (T2), and 10
min after sternum closure (T3).
Assessed postoperative variables included the use of
milrinone, amount of blood loss for postoperative 24 h
(mediastinal and chest tube drainage), and length of ICU
and hospital stay.
Statistical analysis
Continuous variables are presented as mean (SD) or median
(inter-quartile range), and dichotomous variables are pre-
sented as number (percentage). The AUC of the serially mea-
sured troponin-T (four times during 48 h) was calculated
using the trapezoid rule. Dichotomous variables were com-
pared using the x2 or Fisher’s exact tests, as appropriate.
For continuous variables, the normality of distribution was
tested with the Kolmogorov–Smirnov test. Intergroup com-
parisons of parametric data were performed by the inde-
pendent t-test. Intergroup comparisons of non-parametric
data were performed by the Mann–Whitney U-test. Inter-
and intragroup comparisons of parametric data measured
at multiple time points were analysed using the linear
mixed model with patient indicator as a random effect,
group, time, and group by time as fixed effects. Inter- and
intragroup comparisons of non-parametric data measured
at multiple time points were analysed using the Mann–
Whitney U-test with the Bonferroni correction of the resulting
P-values. All statistical tests were two-tailed. P-values of
,0.05 were considered statistically significant. This study
was designed to validate the superiority of GIK treatment.
Based on the results of a previous study, a sample size of
32 patients in each group was determined with 80% power
to detect a 5 ng ml21 (SD 7 ng ml21) difference of CK-MB
between the groups at an a-level of 0.05 using the
GIK and myocardial protection BJA
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independent t-test.15 All statistical analyses were performed
using SAS (version 9.2, Cary, NC, USA).
Results
OPCAB could be successfully performed in all patients
without requiring emergency conversion to an on-pump
procedure. Also, none of the patients required intra-aortic
balloon pump placement during the perioperative period.
Patients’ preoperative characteristics were all similar
between the groups except LVEF which showed a trend
towards being lower in the GIK group compared with the
control group (Table 1).
Operative data including the number of grafts performed
and total graft reconstruction time were similar between
the groups. Serially measured glucose and potassium con-
centrations during the operations were also all similar
between the groups and could be maintained within the pre-
defined target range in all patients (Table 2). In detail, three
patients in the GIK group received both additional 5–10 ml of
50% glucose solution and potassium supplementation (,10
mEq), and one patient in the control group received 3 IU of
regular insulin.
Baseline haemodynamic data were all similar between
the groups. Intraoperative haemodynamic data showed
similar trends of deterioration and recovery during and
after mechanical heart displacement in both groups.
However, SvO2 was significantly higher in the GIK group com-
pared with the control group at T2 (Table 3).
Perioperative changes in myocardial enzymes are listed in
Table 4. Baseline CK-MB concentrations were similar between
the groups, whereas baseline troponin-T was higher in the
GIK group compared with the control group. Highest CK-MB
and troponin-T values after reperfusion reflecting the inten-
sity of myocardial injury were both significantly lower in the
GIK group compared with the control group. All CK-MB and
troponin-T values were significantly increased compared
with each baseline value in both groups (P,0.0001). The
AUC of serially measured troponin-T was also significantly
smaller in the GIK group compared with the control group
[0.83 (0.43–1.81) vs 0.46 (0.31–1.00), P¼0.036]. The
number of patients with troponin-T .0.8 ng ml21 after reper-
fusion was significantly less in the GIK group compared with
the control group.
The number of patients with postoperative MI was,
however, not statistically different between the groups. The
incidence of composite morbidity endpoint and the length
of ICU and hospital stay were also not different between
the groups. One patient died in the control group due to
intractable ventricular dysrhythmia (Table 5).
Discussion
In this randomized and controlled trial addressing the myo-
cardial protective effect of a GIK solution in patients with
Table 2 Operative data. Values are mean (SD), number of patients
(%), or median (inter-quartile range). GIK, glucose–insulin–
potassium
Control
(n533)
GIK
(n533)
P-value
Operation time (min) 320 (44) 334 (47) 0.242
Number of grafts per
patient
3 (3–4) 3 (3–4) 0.653
Total graft reconstruction
time (min)
35 (9) 35 (10) 0.881
Input
Crytalloid (ml) 2391 (729) 2526 (760) 0.511
Colloid (ml) 1074 (255) 1059 (312) 0.842
Packed erythrocytes
(unit)
0.4 (0.8) 0.6 (0.8) 0.451
Urine output (ml) 676 (491) 680 (434) 0.978
Milrinone 7 (22) 6 (19) 1.000
Glucose concentration (mmol litre21)
10 min after anaesthetic
induction
6.6 (1.0) 7.1 (1.3) 0.132
Composite Y graft
construction
7.1 (1.2) 7.0 (1.7) 0.887
10 min after sternum
closure
6.7 (0.9) 6.3 (0.8) 0.134
Potassium concentration (mmol litre21)
10 min after anaesthetic
induction
4.1 (0.3) 4.1 (0.3) 0.577
Composite Y graft
construction
4.1 (0.3) 4.2 (0.3) 0.857
10 min after sternum
closure
4.1 (0.2) 4.1 (0.2) 0.931
Table 3 Intraoperative hemodynamic data. Values are mean (SD).
GIK, glucose–insulin–potassium; T1, 10 min after anaesthetic
induction; T2, 10 min after stabilizer application for grafting at the
obtuse marginalis branch; T3, 10 min after sternum closure.
*P,0.05, intergroup comparison; †P,0.05, intragroup comparison
vs T1
Group
(n533,
each)
T1 T2 T3
Mixed venous oxygen
saturation (%)
Control 78 (5) 66 (9)† 74 (6)
GIK 78 (5) 71 (9)*,† 76 (7)
Cardiac index (litre
min21 m22)
Control 2.8 (0.6) 2.0 (0.4)† 2.6 (0.5)
GIK 2.7 (0.4) 2.2 (0.5)† 2.7 (0.6)
Heart rate (beats min21) Control 60 (6) 65 (11) 70 (8)†
GIK 63 (9) 67 (12) 70 (14)
Mean systemic arterial
pressure (mm Hg)
Control 73 (8) 70 (14) 74 (8)
GIK 73 (8) 68 (8) 73 (7)
Central venous pressure
(mm Hg)
Control 9 (2) 12 (9) 10 (2)
GIK 8 (3) 11 (4)† 10 (3)
Mean pulmonary arterial
pressure (mm Hg)
Control 19 (5) 22 (5)† 20 (4)
GIK 19 (4) 23 (7)† 21 (5)
Pulmonary artery
occlusion pressure (mm
Hg)
Control 13 (4) 16 (4)† 15 (3)
GIK 14 (3) 16 (5) 16 (5)
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ACS undergoing urgent multivessel OPCAB, we observed a
significant attenuation in myocardial injury in terms of sig-
nificant reduction in both peak concentrations of CK-MB
and troponin-T after reperfusion, and also the AUC of the
serially measured troponin-T in the perioperative period in
patients treated with GIK.
Multiple mechanisms involved in attenuating myocardial is-
chaemia–reperfusion injury have been proposed advocating
the use of GIK solution in cardiac surgical setting. The principal
metabolic mechanism involves the optimal provision of glyco-
lytic adenosine triphosphate, which plays a pivotal role in
maintaining membrane integrity during ischaemia. Accord-
ingly, GIK infusion before myocardial ischaemia improves
resistance against myocardial ischaemia.16 17 Another
potential key metabolic mechanism involves the suppression
of the amount of circulating free fatty acids. This promotes
the use of glucose as the primary myocardial fuel source
which is less oxygen consuming,18 and also prevents subse-
quent membrane damage.19 Moreover, GIK improves myocar-
dial perfusion and activates intracellular signalling pathways
involved in inhibiting apoptosis and promoting cell survival
suggesting its additional role in attenuating subsequent myo-
cardial injury after reperfusion.20 21 Other non-metabolic
effects include improved cardiac output by decreasing system-
ic vascular resistance and direct positive inotropic effect on the
post-ischaemic heart.22 23
Despite these theoretical advantages, however, the wide-
spread use of GIK solution in cardiac surgical setting had
been limited by inconclusive clinical results.24 25 This contro-
versy may be attributable to wide ranges of insulin dosages
used and the inconsistent duration and timing of GIK admin-
istration. Earlier studies administered suboptimal insulin
dosage not sufficient enough to suppress circulating free
fatty acid concentrations or failed to administer GIK solution
into the reperfusion period. Also, inconsistent glycaemic
control may have masked the beneficial effects conveyed
by the GIK solution, since hyperglycaemia is known to inde-
pendently aggravate the extent of myocardial injury.26
Nevertheless, neither serious nor life-threatening complica-
tions have been reported so far,14 27 28 and a more recent
meta-analysis addressing the effects of GIK solution in
adult cardiac surgical patients revealed significant reduction
in myocardial injury and improvement in haemodynamic
performance.11
With regard to GIK application in OPCAB, however, only a
limited number of studies exist reporting either neutral or
negative results.29 – 31 Although all of these studies used ap-
propriate insulin dosages to suppress free fatty acids (≥5 IU
h21),18 and administered GIK solution into the reperfusion
period, none of these studies could demonstrate attenuation
of myocardial injury. In these studies, the lack of beneficial
influence was explained by including low-risk patients and
the absence of evident myocardial ischaemia–reperfusion
injury associated with OPCAB. This was supported by the
Table 4 Perioperative changes in myocardial enzymes. Values are mean (SD), number of patients (%), or median (inter-quartile range). GIK,
glucose–insulin–potassium
Control (n533) GIK (n533) P-value
Creatine kinase-MB (ng ml21)
Preoperative 4.0 (0.9) 3.9 (1.3) 0.871
Highest value after reperfusion 13.1 (7.9) 8.7 (4.4) 0.006
Troponin-T (ng ml21)
Preoperative 0.02 (0.01–0.05) 0.04 (0.01–0.08) ,0.001
12 h after reperfusion 0.34 (0.12–0.83) 0.19 (0.12–0.49) 0.183
24 h after reperfusion 0.36 (0.16–0.72) 0.17 (0.11–0.34) ,0.001
48 h after reperfusion 0.28 (0.12–0.51) 0.10 (0.06–0.23) ,0.001
Highest value after reperfusion 0.48 (0.18–0.91) 0.20 (0.13–0.49) ,0.001
Troponin-T .0.8 ng ml21 11 (33) 3 (9) 0.033
Table 5 Postoperative data and outcome. Values are mean (SD) or
number of patients (%). GIK, glucose–insulin–potassium; ICU,
intensive care unit
Control
(n533)
GIK
(n533)
P-value
Glucose at 4 h after ICU arrival
(mg dl21)
150 (29) 147 (31) 0.659
Potassium at 4 h after ICU
arrival (mmol litre21)
4.1 (0.2) 4.2 (0.3) 0.567
Milrinone 8 (24) 6 (18) 0.764
Postoperative 24 h bleeding
(ml)
543 (251) 522 (281) 0.761
Composite morbidity endpoint 12 (36) 7 (21) 0.277
Stroke 0 0 1.000
Haemostatic reoperation 1 (3) 1 (3) 1.000
Deep sternal wound
infection
1 (3) 2 (6) 1.000
Renal dysfunction 3 (9) 3 (9) 1.000
Ventilator care . 48 h 2 (6) 0 0.492
Myocardial infarction 4 (12) 1 (3) 0.355
In-hospital mortality 1 (3) 0 1.000
Length of ICU stay (days) 3.6 (1.5) 3.4 (1.7) 0.540
Length of hospital stay (days) 15.9 (6.0) 15.4 (4.3) 0.676
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findings of previous studies demonstrating less myocardial
injury associated with OPCAB compared with on-pump
CABG.32 33
Patients with ACS display a high-risk entity among
patients undergoing CABG, and OPCAB is gaining renewed
interest in those patients as it has been safely performed
with better results compared with on-pump CABG.5 34
However, OPCAB requires brief obligatory periods of regional
myocardial ischaemia for target vessel anastomosis leading
to various degrees of myocardial injury. In addition, mechan-
ical heart displacement results in reduced cardiac output
which may further aggravate the regional ischaemic insult
imposed on the myocardium. As these insults become cumu-
lative in the case of multivessel grafting, patients with evolv-
ing MI, unstable angina, or both requiring urgent multivessel
OPCAB would be more prone to develop significant myocar-
dial injury. These aspects have led us to our hypothesis
that ACS patients requiring urgent multivessel OPCAB would
most likely benefit from metabolic myocardial protection
with GIK solution, yet it has never been addressed
heretofore.
As our results indicate, insulin infusion at a rate of 0.195
IU kg21 h22 starting immediately after anaesthetic induction
until 6 h after reperfusion offered significant ischaemic
benefit in terms of postoperative myocardial enzyme
release in ACS patients undergoing urgent multivessel
OPCAB. Both, highest CK-MB and troponin-T after reperfusion
indicating the intensity of myocardial injury were significant-
ly higher in the control group compared with the GIK group,
despite higher baseline troponin-T values in the GIK group.
Moreover, the AUC of the serially measured troponin-T was
also significantly smaller in the GIK group compared with
the control group. In addition, significantly fewer patients
showed troponin-T .0.8 ng ml21 in the GIK group compared
with the control group in the current trial.
Notwithstanding the lack of statistically significant clinical
benefit in the current trial, cardiac enzymes have been used
as surrogate markers of myocardial injury and patients’
outcome after CABG. Troponins have the improved ability to
diagnose subtle ischaemic injuries and perioperative myocar-
dial ischaemia compared with CK-MB, and are considered as
the preferred biomarkers for assessing myocardial injury.35
Indeed, a recent retrospective analysis involving a large con-
temporary cohort of adult cardiac surgical patients revealed
that troponin-T concentrations of more than 0.8 ng ml21
were independently associated with major adverse cardiac
events after surgery with the largest odds risk ratio (2.7,
95% confidence interval: 2.08–3.5) compared with other in-
dependent risk factors.12 Thus, the results of the current
trial suggest the beneficial influence of the GIK solution on
attenuating OPCAB-related myocardial injury in ACS patients.
More importantly, these benefits could be observed
without the occurrence of insulin-resistant hyperglycaemia
which was reported by a previous study applying GIK in
OPCAB.30 In that study, patients with higher preoperative
glucose concentrations up to 19.4 mmol litre21 were
included, and a different regimen and infusion rate of GIK
solution was applied compared with our study. In the
current trial, we used a modified GIK regimen from our pre-
vious study which delivers a concentration of insulin suffi-
cient to suppress circulating free fatty acids and yielding
improved glycaemic control.29 Accordingly, none of our
patients was exposed to a blood glucose concentration of
more than 11 mmol litre21 throughout the study period.
However, as noted above, we excluded patients with
preoperative fasting glucose concentration .13.8 mmol
litre21. Since, acute systemic inflammatory response asso-
ciated with an evolving MI may evoke hyperglycaemic epi-
sodes, caution should be exercised not to extrapolate the
results of the current trial to patients with poorly controlled
blood glucose concentrations in the preoperative period.
Of interest, SvO2 was significantly higher in the GIK group
during grafting at the obtuse marginalis branch with a con-
comitant trend towards a higher cardiac index in the GIK
group. This may be the consequence of a possible direct ino-
tropic action of insulin rather than the consequence of meta-
bolic protection of the myocardium, considering that SvO2
was similar between the groups during other periods of graft-
ing and that haemodynamic deterioration by mechanical
heart displacement is most severe during exposure of the
obtuse marginalis branch.9
The limitation of this study is as follows. Contrary to the
definite benefit observed in terms of myocardial injury as
reflected by CK-MB and tropoinin-T, the sample size may
have been too small to identify differences in actual clinical
outcome such as the incidence of postoperative MI.
In conclusion, continuous infusion of GIK solution starting
upon anaesthetic induction until 6 h after reperfusion in ACS
patients undergoing urgent multivessel OPCAB could signifi-
cantly attenuate the degree of ensuing myocardial injury as
assessed by CK-MB and troponin-T. As this regimen was
devoid of insulin-resistant hyperglycaemia, consideration
should be given to use this simple and inexpensive thera-
peutic measure of metabolic myocardial protection for
patients at increased risk of developing major adverse
cardiac events after OPCAB.
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